Opinion|Videos|November 25, 2024
Operationalizing Bispecific Therapy and the Impact of CAR T Advancements on Sequencing
Panelists discuss how advances in bispecific antibodies and CAR T-cell therapies are transforming treatment approaches for relapsed/refractory multiple myeloma, while presenting complex operational challenges that require innovative institutional strategies.
Advertisement
Video content above is prompted by the following:
- How has this impacted sequencing of bispecific antibodies and CAR T-cell therapy for patients at your institution?
- What operational challenges do institutions often face in terms of the use of bispecific antibodies in patients with RRMM, and how has your institution addressed these challenges?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- IVIG Therapy Reduced Infections by 67% in Patients With Multiple Myeloma
September 19th 2025
- IMS 2025: Shifting Immunotherapies to Outpatient Care for Multiple Myeloma
September 19th 2025
- IMS 2025: Improving Outcomes with Bispecifics in Multiple Myeloma
September 19th 2025
- IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
ACIP Meeting: COVID-19 Vaccines to be Administered Through Shared Clinical Decision-Making
2
ACIP Meeting: Combined MMRV Vaccine, Hepatitis B Vaccine Restricted for Some Age Groups
3
Intelligent Pharmacy: Leveraging AI and Automation to Enhance Patient Care and Pharmacist Roles
4
FDA Approves Keytruda Qlex Subcutaneous Injection for Adult and Pediatric Patients With Solid Tumors
5